- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06628349
Prandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein
November 19, 2025 updated by: Marielle PKJ Engelen, PhD, Texas A&M University
The researchers overall objective is to determine whether plant and animal protein based proteins affect the anabolic responses across aging populations differently due to specific changes in the essential amino acids (EAA) and non-essential amino acids (NEAA) kinetic responses.
The researchers central hypothesis is that a high EAA to NEAA ratio in a protein meal is related to higher anabolic response to the meal.
The researchers also hypothesize that the type of NEAA in a protein meal also affects the anabolic capacity of the meal.
The researchers rationale is that finding the amino acid composition of a meal that will maximally induce protein anabolism will guide novel nutritional approaches to prevent and treat sarcopenia, thereby reducing both overall economic burden and improving individual patient outcomes.
Study Overview
Status
Recruiting
Conditions
Detailed Description
The study will be conducted in sarcopenic and non-sarcopenic older adults, stratified into different age categories.
A sip feeding model will be used as it is a good model to establish the anabolic capacity of meals.
The researchers hypothesize that plant-based protein induces less protein anabolism, due to lower production of EAA and higher production of non-essential amino acids (NEAA) as compared to dairy protein.
The NEAA kinetics will be different between the plant proteins as soy protein has relatively high levels of the NEAA arginine and Pea protein of aspartate/glutamate.
The researchers results will guide future nutritional advice on replacing daily protein with plant-based proteins while keeping the overall effects on metabolism comparable for both the EAA and NEAA.
The study will take place at the research facility of the Center for Translational Research on Aging and Longevity (CTRAL), Texas A&M University located in the Human Clinical Research Building ) affiliated with Texas A&M University.
The study involves 1 screening visit of approx.
3 hours, and 4 study days.
Some study procedures (e.g., body composition, skeletal muscle function, questionnaires) may be skipped if completed within the past 3 months at CTRAL.
All data will be recorded in Case Report Form and stored in the Texas A&M REDCap System.
Subjects will be asked to arrive in the fasted state on all study days.
Fasting prior to screening is not required.
On the screening day, body weight, height, and body composition by Dual-energy X-ray absorptiometry (DXA) will be measured.
In addition, The Six-Minute Walk Test (6MWT) and skeletal muscle function tests will be assessed at the end of each screening visit.
Each study visit will begin with vital signs.
Before administration of the feeding or the tracer solution, baseline blood will be collected for measurement of the natural enrichment of metabolites.
After the baseline sample is collected, feeding will begin and will be followed by tracers of several compounds that may be administered by IV pulse.
Participants will receive the liquid nutritional supplement as sip feeds every 20 minutes for 5 hours.
The liquid nutrition supplements will contain the following proteins: (1) 45g of whey protein (dairy based), (2) 45g of soy protein (plant based), (3) 45g of pea protein (plant based), or (4) Placebo (water).
Participants will have the option of adding sugar free (SF) vanilla syrup, SF caramel syrup, or SF chocolate syrup to their meals.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marielle Engelen, PhD
- Phone Number: 979-220-2282
- Email: mpkj.engelen@ctral.org
Study Contact Backup
- Name: Savanah Knezek, BS
- Phone Number: 979-442-8468
- Email: research@ctral.org
Study Locations
-
-
Texas
-
College Station, Texas, United States, 77845
- Recruiting
- Texas A&M University - CTRAL
-
Contact:
- Laura Ruebush
- Phone Number: 979-218-5515
- Email: le.ruebush@ctral.org
-
Principal Investigator:
- Nicolaas E Deutz, MD, PhD
-
Sub-Investigator:
- Marielle P Engelen, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age 50-95 years old
- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD); COPD group only
- Stable body-weight (±5%) for the past 3 months
- Ability to walk, sit down, and stand up (independently or with walking assistance device)
- Willingness to lay supine in bed for up to 6 hours
- Willingness and ability to comply with the protocol
Exclusion Criteria:
- Established diagnosis and active treatment of chronic disease: Insulin dependent diabetes mellitus, active malignancy, heart disease, kidney disease, liver disease, HIV/AIDS, Asthma (moderate to severe), Hep (A,B, or C)
- History of untreated metabolic disease including hepatic or renal disorder
- Presence of acute illness or metabolically unstable chronic illness
- Hysterectomy
- Active dependence of alcohol or drugs
- Use of short course of oral corticosteroids within 4 weeks preceding study day
- Current use of long-term oral corticosteroids
- Use of protein or amino acids containing nutritional supplements within 5 days of the first study day
- Presence of fever within the last 3 days
- Planned elective surgery requiring 2 or more days of hospitalization during the entire study
- (Possible) pregnancy
- Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject
- Already enrolled in another clinical trial
- Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
- Known allergy to any of the components of the feeding (soy, pea, or whey - dairy)
- Established daily diet of vegetarian / vegan composition
- <23 MoCa score
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Healthy male older adults
Dietary Supplement: Whey Protein Isolate 90%.
Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein).
Commercially available Dietary Supplement: Organic Pea Protein Isolate.
Commercially available Dietary Supplement: Placebo - Water
|
Commercially available animal based protein powders
Commercially available plant based protein powders
Commercially available plant based protein powders
Normal drinking water
|
|
Experimental: Healthy female older adults
Dietary Supplement: Whey Protein Isolate 90%.
Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein).
Commercially available Dietary Supplement: Organic Pea Protein Isolate.
Commercially available Dietary Supplement: Placebo - Water
|
Commercially available animal based protein powders
Commercially available plant based protein powders
Commercially available plant based protein powders
Normal drinking water
|
|
Experimental: Healthy male old older adults
Dietary Supplement: Whey Protein Isolate 90%.
Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein).
Commercially available Dietary Supplement: Organic Pea Protein Isolate.
Commercially available Dietary Supplement: Placebo - Water
|
Commercially available animal based protein powders
Commercially available plant based protein powders
Commercially available plant based protein powders
Normal drinking water
|
|
Experimental: Healthy female old older adults
Dietary Supplement: Whey Protein Isolate 90%.
Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein).
Commercially available Dietary Supplement: Organic Pea Protein Isolate.
Commercially available Dietary Supplement: Placebo - Water
|
Commercially available animal based protein powders
Commercially available plant based protein powders
Commercially available plant based protein powders
Normal drinking water
|
|
Experimental: Sarcopenic male old older adults
Dietary Supplement: Whey Protein Isolate 90%.
Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein).
Commercially available Dietary Supplement: Organic Pea Protein Isolate.
Commercially available Dietary Supplement: Placebo - Water
|
Commercially available animal based protein powders
Commercially available plant based protein powders
Commercially available plant based protein powders
Normal drinking water
|
|
Experimental: Sarcopenic female old older adults
Dietary Supplement: Whey Protein Isolate 90%.
Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein).
Commercially available Dietary Supplement: Organic Pea Protein Isolate.
Commercially available Dietary Supplement: Placebo - Water
|
Commercially available animal based protein powders
Commercially available plant based protein powders
Commercially available plant based protein powders
Normal drinking water
|
|
Experimental: COPD male older adults
Dietary Supplement: Whey Protein Isolate 90%.
Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein).
Commercially available Dietary Supplement: Organic Pea Protein Isolate.
Commercially available Dietary Supplement: Placebo - Water
|
Commercially available animal based protein powders
Commercially available plant based protein powders
Commercially available plant based protein powders
Normal drinking water
|
|
Experimental: COPD female older adults
Dietary Supplement: Whey Protein Isolate 90%.
Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein).
Commercially available Dietary Supplement: Organic Pea Protein Isolate.
Commercially available Dietary Supplement: Placebo - Water
|
Commercially available animal based protein powders
Commercially available plant based protein powders
Commercially available plant based protein powders
Normal drinking water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Protein and amino acid synthesis capacity of plant-based and animal-based protein in older adults with or without sarcopenia measured by the use of stable isotope tracers
Time Frame: 4 weeks
|
A novel stable isotope technique will be used to assess simultaneously the anabolic response and whole body production rates of a variety of amino acids to intake of both dietary proteins in sarcopenic older participants.
The samples will be stored in laboratory freezers and the amino acid isotope enrichments and concentrations analyzed by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS).
The researchers will then conduct LC-MS/MS analysis, peak integration, calculation of amino acid concentrations and whole body productions from raw data, and use the results for preparation of papers for presentation, publication, and final reports.
The researchers main hypothesis is that plant-based protein induces less protein anabolism, due to lower whole body production of essential amino acids (EAA) and higher production of non-essential amino acids (NEAA) as compared to dairy protein.
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nicolaas Deutz, MD, PhD, Texas A&M University
- Principal Investigator: Marielle Engelen, PhD, Texas A&M University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2024
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
April 26, 2024
First Submitted That Met QC Criteria
October 3, 2024
First Posted (Actual)
October 4, 2024
Study Record Updates
Last Update Posted (Actual)
November 25, 2025
Last Update Submitted That Met QC Criteria
November 19, 2025
Last Verified
November 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Muscular Atrophy
- Atrophy
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Sarcopenia
- Amino Acids, Peptides, and Proteins
- Food
- Diet, Food, and Nutrition
- Physiological Phenomena
- Food and Beverages
- Inorganic Chemicals
- Anions
- Ions
- Electrolytes
- Hydroxides
- Alkalies
- Oxides
- Oxygen Compounds
- Plant Proteins, Dietary
- Dietary Proteins
- Plant Proteins
- Soy Foods
- Vegetable Products
- Vegetables
- Water
- Proteins
- Soybean Proteins
Other Study ID Numbers
- 94- Plant Protein Sips
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Data may be shared upon request for up to 6 years beyond completion of the trial based on methods/proposals approved by both parties' institutional review committees.
Individual participant data that underlie the results of the trial may be shared after de-identification (text, tables, figures, and appendices).
Additional documents available per request include: study protocol, statistical analysis plan, and informed consent.
Requests should be directed to Dr. Marielle Engelen (mpkj.engelen@ctral.org).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Protein Metabolism
-
University of Illinois at Urbana-ChampaignCompletedMuscle Protein Synthesis | Protein MetabolismUnited States
-
Maastricht University Medical CenterNot yet recruitingProtein MetabolismNetherlands
-
University of Illinois at Urbana-ChampaignBIO-CAT, Inc.CompletedProtein MetabolismUnited States
-
University of ArkansasCompletedProtein MetabolismUnited States
-
University of Illinois at Urbana-ChampaignCompletedProtein MetabolismUnited States
-
University of AarhusInnovation Fund Denmark; Arla Foods; Team DenmarkCompletedProtein Metabolism
-
Maastricht University Medical CenterRecruitingAmino Acid Oxidation of Whole-Food Protein: a Dose-Response Crossover Trial in Young Adults (BURGER)Protein MetabolismNetherlands
-
University of TorontoRecruiting
-
Texas A&M UniversityRecruitingProtein MetabolismUnited States
-
Daniel MooreLesaffre InternationalRecruiting
Clinical Trials on Whey Protein Isolate 90%
-
INQUIS Clinical ResearchCompletedPrediabetes | Normoglycemia | Normal Plasma GlucoseCanada
-
Daniel MooreLesaffre InternationalRecruiting
-
Musclegen Research, Inc.CompletedAbsorption; Disorder, Protein | Analysis, Event History
-
University of WestminsterCoventry UniversityCompletedAppetite and General Nutritional DisordersUnited Kingdom
-
NestléCompleted
-
Federal University of Health Science of Porto AlegreCompleted
-
University of FloridaCompletedRenal Failure | Chronic Kidney Disease Requiring Chronic DialysisUnited States
-
Syracuse UniversityDairy Research InstituteCompletedBlood PressureUnited States
-
Nova Southeastern UniversityImmunotec Inc.CompletedAutism Spectrum DisordersUnited States
-
Loughborough UniversityVolac International LimitedRecruitingAgeing Well | Neuromuscular FunctionUnited Kingdom